β1-receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery

Leanne Dumeny1 | Marut Chantra2 | Taimour Langaee1 | Benjamin Q. Duong1 |
Daniel H. Zambrano1 | Frank Han3 | Dalia Lopez-Colon3 | James F. Humma1 |
Jonathan Dacosta1 | Tommie Lovato1 | Connie Mei1 | Julio D. Duarte1 |
Julie A. Johnson1 | Giles J. Peek3 | Jeffrey P. Jacobs3 | Mark S. Bleiweis3 |
Larisa H. Cavallari1

1Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA
2Division of Pediatric Critical Care, Departments of Pediatrics, College of Medicine, University of Florida, Gainesville, Florida, USA
3Division of Cardiovascular Surgery, Departments of Surgery and Pediatrics, Congenital Heart Center, College of Medicine, University of Florida, Gainesville, Florida, USA

Correspondence
Larisa H. Cavallari, Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, PO Box 100846, Gainesville, FL 32610, USA. Email: lcvallari@cop.ufl.edu

Present address
Marut Chantra, Division of Pediatric Critical Care Medicine, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Ratchatewi, Bangkok, Thailand
Benjamin Q. Duong, Precision Medicine, Nemours Children’s Health, Wilmington, Delaware, USA

Funding information
Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under University of Florida Clinical and Translational Science Awards TL1TR001428 and UL1TR001427, and National Heart, Lung, and Blood Institute of the National Institutes of Health award number F31HL154563 awarded to L.D.

Abstract
Junctional ectopic tachycardia (JET) is a potentially life-threatening postoperative arrhythmia in children with specific congenital heart defects and can contribute significantly to postoperative morbidity for at-risk populations. In adults, β1-adrenergic receptor (ADRB1) and β2-adrenergic receptor (ADRB2) genotypes have been associated with increased risk for arrhythmias. However, their association with arrhythmia risk in children is unknown. We aimed to test associations between ADRB1 and ADRB2 genotypes and postoperative JET in patients with congenital heart defects. Children who underwent cardiac surgery were genotyped for the ADRB1 p.Ser49Gly (rs1801252; c.145A>G), p.Arg389Gly (rs1801253; c.1165C>G), ADRB2 p.Arg16Gly (rs1042713; c.46A>G), and p.Glu27Gln (rs1042714; c.79G>C) polymorphisms. The occurrence of postoperative JET was assessed via cardiologist-interpreted electrocardiograms. Genotype associations with JET were analyzed via logistic regression, adjusted for clinical variables associated with JET, with separate analysis in patients not on a β-blocker. Of the 343 children included (median age 8 months, 53% boys, 69% European ancestry), 45 (13%) developed JET. The Arg389Arg genotype was not significantly associated with JET in the overall population (odds ratio [OR] = 1.96, 95% confidence interval [CI] = 0.96–4.03, p = 0.064), but was nominally associated in patients not taking a β-blocker (n = 324, OR = 2.25, 95% CI = 1.05–4.80, p = 0.034). None of the other variants were associated with JET. These data suggest that the ADRB1 Arg389Arg genotype may predict risk for JET following cardiac surgery.
INTRODUCTION

Postoperative arrhythmia is a major cause for morbidity and mortality in children undergoing cardiac surgery for repair of congenital heart defects (CHD). Junctional ectopic tachycardia (JET) is a potentially life-threatening postoperative arrhythmia occurring in 10% to 15% of patients in this setting and is especially common following repair of atrioventricular septal defect, ventricular septal defect, or Tetralogy of Fallot. The morbidity associated with JET leads to prolonged ventilation time, increased intensive care unit (ICU) length of stay, and higher ICU mortality. Ideally, if risk of JET could be predicted preoperatively, measures could be undertaken to prevent or minimize its occurrence postoperatively.

β-adrenergic receptors play a significant role in the regulation of heart rate, cardiac contractility, and cardiac electrical activity. The β1- and β2-adrenergic receptors are encoded by the ADRB1 and ADRB2 genes, respectively. The ADRB1 p. Ser49Gly (rs1801252; c.145A>G) and p. Arg389Gly (rs1801253; c.1165C>G) polymorphisms as well as the ADRB2 p. Arg16Gly (rs1042713; c.46A>G) and p. Gln27Glu (rs1042714; c.79G>C) polymorphisms have been associated with altered adrenergic receptor signaling in vitro. Specifically, the ADRB1 Ser49 and Arg389 alleles confer greater agonist-mediated response, and the ADRB2 Gly16 and Gln27 alleles lead to enhanced agonist-mediated receptor downregulation and increased agonist-mediated responsiveness, respectively. Among adults undergoing cardiac surgery, the ADRB1 Arg389Gly polymorphism was associated with an increased risk for postoperative atrial fibrillation. In a case-control study of patients with idiopathic ventricular arrhythmias, the ADRB2 Gly16 and Glu27 variants were linked to increased risk of ventricular arrhythmias. However, the contribution of these variants to arrhythmia risk in children with CHD is unknown. The purpose of this study was to investigate the association among ADRB1 Ser49Gly, ADRB1 Arg389Gly, ADRB2 Arg16Gly, and ADRB2 Gln27Glu genotypes and postoperative JET occurrence in children undergoing cardiac surgery.

METHODS

Study population

The Molecular Genetics of Pediatric Patients with Congenital Heart Disease Sample and Data Bank (hereafter referred to as the CHD Bank) included data and samples for genetic analysis from pediatric patients (age ≤21 years) who underwent cardiac surgery at the University of Florida between 2012 and 2017. This study was approved by the University of Florida Institutional Review Board for Research on Human Subjects. Written informed consent was obtained from each patient included in this analysis, or from his/her parent or legal guardian.
Data and sample collection

A blood or buccal cell sample for genetic analysis was collected prior to or during cardiac surgery. Demographic and clinical data from the time of the hospitalization associated with surgery were manually abstracted from the electronic health record and entered into the CHD Bank. Electrocardiograms (ECGs) done between the operation and hospital discharge were reviewed by a pediatric cardiologist to determine the occurrence of postoperative JET. Using self-reported race from the electronic health record (i.e., White, Black, or Asian), patient ancestries were categorized as European, African, or other.

Genotyping

DNA was extracted from blood or buccal cells using the FlexiGene DNA Kit (Qiagen, Valencia, CA). DNA concentration and quality were assessed via a NanoDrop 2000c Spectrophotometer (Thermo Fisher Scientific, Waltham, MA). Genotyping of the ADRB1 Ser49Gly (rs1801252), ADRB1 Arg389Gly (rs1801253), ADRB2 Arg16Gly (rs1042713), and ADRB2 Glu27Gln (rs1042714) polymorphisms was performed via TaqMan Assay on a QuantStudio 12k Flex (Thermo Fisher Scientific) genotyping platform. Given the linkage disequilibrium between the ADRB1 Ser49Gly and Arg389Gly genotypes, we also investigated the association between the ADRB1 haplotype and risk for JET. The number of haplotype copies for ADRB1 Ser49Arg389 was generated using the genotype data with PHASE version 2.1.1.

Statistical analysis

Clinical and operative characteristics were compared between patients with and without JET occurrence using a t-test for continuous data and chi-square analysis for categorical data. Because of lower frequencies of the homozygous variants, the ADRB1 Ser49Gly, Arg389Gly, and ADRB2 Glu27Gln genotypes were tested using the dominant model. For the ADRB2 Arg16Gly genotype, the Gly16 variant is the major allele and so the recessive model was used for consistency. Associations between genotype or haplotype and JET were analyzed using a multivariable logistic regression model. Regression models were adjusted for variables previously shown to be associated with pediatric postoperative JET, such as age, sex, procedures at high-risk for postoperative JET, aortic cross-clamp (ACC) time, cardiopulmonary bypass time (CPB), inotrope use, and β-blocker use. Body surface area was not included in this adjustment because of its significant correlation (r = 0.94) with age. Procedures considered high-risk for postoperative JET were arterial switch procedure, atrioventricular septal defect repairs, Fontan procedure, Norwood procedure, tetralogy of Fallot (TOF) repair, total anomalous pulmonary venous return repair, and ventricular septal defect repair. Based on the number of participants enrolled in this prospective cohort, we had 80% power to detect an odds ratio (OR) of two for the ADRB1 Arg389Gly genotype.

Because β-blockers may attenuate any effect of genotype on arrhythmia risk, a prespecified subgroup analysis was performed in patients without recorded use of perioperative β-blockers prior to JET occurrence. All analyses were performed using R version 4.0.2.

RESULTS

A total of 343 patients from the CHD Bank were included in the analysis. The median age of the overall population was 7.9 months (interquartile range [IQR]: 1.6–59.9 months); 183 (53%) patients were boys, and 235 (69%) were of European ancestry (Table 1). The most common surgical procedures were atrial septal defect repair and ventricular septal defect repair, with 124 (36%) patients undergoing a combination of procedures. One hundred sixty-two (47%) patients underwent at least one procedure deemed high-risk for postoperative JET. A total of 161 (47%) patients received inotropic support prior to the occurrence of JET (161; 47%), most commonly with milrinone (154; 45%) and epinephrine (119; 35%). Nineteen patients (6%) were started on β-blocker therapy prior to JET occurrence.

Genotype frequencies were consistent with previously reported frequencies (Table 2), and all single nucleotide polymorphisms (SNPs) were in Hardy Weinberg equilibrium.

Overall, 45 (13%) patients developed JET. Consistent with previous reports, patients with JET were significantly younger, of smaller body size, underwent more procedures deemed high-risk for postoperative JET, and had longer ACC and CPB times (Table 1). In the population overall, there was no significant association between the ADRB1 Arg389Arg genotype and risk for JET (adjusted p = 0.064). However, in the subset of patients who were not taking a β-blocker prior to JET occurrence, the Arg389Arg genotype was nominally associated with an increased risk for JET (adjusted OR = 2.25, 95% confidence interval [CI] = 1.05–4.80, adjusted p = 0.034).

There were no associations between JET and ADRB1 Ser49Gly, ADRB2 Arg16Gly, or ADRB2 Glu27Gln genotypes in the population overall or in patients not treated with a β-blocker prior to JET occurrence (Table 3).
was also no significant association between Ser49Arg389 haplotype and JET in the population overall (p = 0.068) or among patients not on β-blockers (p = 0.064).

**DISCUSSION**

In this study, the **ADRB1** Arg389Arg genotype was associated with JET occurrence following cardiac surgery in pediatric patients not on a β-blocker, but not when considering all patients. The etiology of postoperative arrhythmias after pediatric and congenital cardiac surgery is multifactorial; however, adrenergic activation has been implicated in the pathogenesis of arrhythmias. Postoperative arrhythmias are specifically hypothesized to occur due to stress-induced catecholamine release (i.e., adrenergic stimulation) during surgery. Variation in adrenergic signaling has been reported secondary to the **ADRB1** Arg389Arg genotype, with increased agonist-stimulated adenylyl cyclase activity with the Arg389 versus Gly389 allele. Conversely, Gly389 is associated with decreased G-protein coupling of the β1-adrenergic receptor, and consequently, a reduction of cyclic AMP levels. Therefore, it is plausible that an increased risk of

| TABLE 1 | Clinical and operative characteristics |
|---|---|---|---|---|---|---|
| Age, months | 7.9 (1.6–59.9) | 2.3 (0.4–8.2) | 10.3 (2.7–65.5) | 2.76 × 10⁻⁶ |
| Male sex | 183 (53%) | 22 (54%) | 161 (48%) | 0.519 |
| Ancestry |  |  |  |  |
| European | 235 (69%) | 205 (66%) | 30 (68%) | 0.875 |
| African | 70 (20%) | 61 (20%) | 9 (20%) |  |
| Other | 38 (11%) | 32 (13%) | 6 (10%) |  |
| Body surface area, m² | 0.58 ± 0.48 | 0.36 ± 0.28 | 0.62 ± 0.50 | 2.40 × 10⁻⁶ |
| Aortic cross-clamp time, min | 55.1 ± 32.2 | 65.2 ± 31.5 | 53.4 ± 32.1 | 0.029 |
| Cardiopulmonary bypass time, min | 89.4 ± 48.0 | 103.4 ± 44.0 | 87.1 ± 48.3 | 0.026 |
| Surgical procedure¹ |  |  |  |  |
| Procedure for high-risk for postoperative JET | 162 (47%) | 36 (80%) | 126 (42%) | 2.31 × 10⁻⁶ |
| ASD repair | 102 (30%) | 20 (44%) | 82 (28%) |  |
| VSD repair | 77 (22%) | 21 (47%) | 56 (29%) |  |
| TOF repair | 30 (8%) | 11 (24%) | 19 (6%) |  |
| AVSD repair | 28 (8%) | 5 (11%) | 23 (8%) |  |
| Norwood | 20 (6%) | 3 (7%) | 17 (6%) |  |
| Perioperative medications |  |  |  |  |
| β-blocker use | 19 (6%) | 3 (7%) | 16 (5%) | 0.723 |
| Inotrope use ² | 161 (47%) | 135 (58%) | 26 (45%) | 0.118 |

Note: Mean ±SD, median (interquartile range [IQR]), or N (%).
Abbreviations: AA, aortic arch; ASD, atrial septal defect; AVSD, atrioventricular septal defect; JET, junctional ectopic tachycardia; TOF, tetralogy of Fallot; VSD, ventricular septal defect.

¹Some patients underwent multiple concurrent procedures.
²Consisted of milrinone (n = 154, 45%) and epinephrine (n = 119, 35%).

| TABLE 2 | Frequencies of **ADRB1** and **ADRB2** genotypes |
|---|---|---|---|
| **Gene** | **Codon** | **Genotype** | **N (%)** |
| **ADRB1** | 49 | Ser49Ser | 234 (68%) |
|  |  | Ser49Gly | 99 (29%) |
|  |  | Gly49Gly | 10 (3%) |
|  | 389 | Arg389Arg | 179 (52%) |
|  |  | Gly389Arg | 133 (39%) |
|  |  | Gly389Gly | 31 (9%) |
| **ADRB2** | 16 | Arg16Arg | 59 (17%) |
|  |  | Gly16Arg | 156 (45%) |
|  |  | Gly16Gly | 128 (37%) |
|  |  | Gln27Gln | 161 (47%) |
|  |  | Gln27Glu | 138 (40%) |
|  |  | Glu27Glu | 44 (13%) |
cardiovascular-related events, and specifically susceptibility for arrhythmia, may occur secondary to the greater catecholamine-mediated response with the Arg389 allele. In contrast to our findings, a study of adults undergoing cardiac surgery reported that the Gly389Gly genotype was associated with an increased risk for postoperative atrial fibrillation. However, our findings are consistent with other studies in adult populations with cardiac disease showing a higher prevalence of ventricular arrhythmias with the Arg389Arg genotype. Our findings (and those of others) may be explained by decreased β-adrenergic receptor signaling associated with the Gly allele, potentially providing protection against tachycardia-inducing sympathetic surges, which can occur during surgery. The association we observed in patients untreated versus treated with β-blockers indicates that preemptive β-blocker administration could potentially attenuate the risk of postoperative JET associated with the Arg389Arg genotype. Evidence suggests that adrenergic antagonists—via reductions in adrenergic stimulation—decrease the risk of JET and could be a potential preventive therapy. Specifically, dexmedetomidine, an α2-adrenergic receptor agonist with sympatholytic effects, decreases the incidence of postoperative JET.

Similarly, pre-operative use of propranolol, a nonselective β-blocker, reduced the incidence of postoperative JET after TOF repair. Our data suggest that β-blockers may specifically attenuate the risk associated with the ADRB1 genotype for postoperative JET occurrence in children undergoing cardiac surgery. Similarly, Pacanowski et al. found that, compared to verapamil treatment, atenolol reduced the risk for death among patients with hypertension with the ADRB1 Ser49Arg389 haplotype. Although not reaching statistical significance, we observed a trend in association between this haplotype and risk for JET. β-blockers have also been shown to modify the effect of the Arg389Arg genotype on nonsurgical arrhythmia risk, as reported in a genetic substudy of the β-Blocker Evaluation of Survival Trial in patients with heart failure. The increased risk for ventricular tachycardia and fibrillation observed with the Arg389Arg genotype in the placebo arm was attenuated with bucindolol treatment. Conversely, bucindolol treatment had no impact on arrhythmia risk in Gly389 allele carriers. Whereas these data help to support the use of β-blockers to potentially attenuate an arrhythmogenic genotype effect, considering the small number of patients taking β-blockers in our study, our results should be considered hypothesis-generating, and additional studies are needed to determine whether prophylactic use of β-blockers may reduce the risk for JET in pediatric patients undergoing procedures deemed high-risk for postoperative JET based on genotype.

We acknowledge a few limitations in our study. In addition to the small number of patients treated with β-blockers, our overall total cohort was relatively small, and we were underpowered to detect smaller effect sizes and to detect haplotype associations. Data on use of dexmedetomidine was not available in the CHD Bank and, thus, we were unable to account for any potential effects of the drug on the occurrence of JET. We also did not consider the role of other SNPs that may be associated with the incidence of postoperative JET. In particular, the GRK5 gene encodes GRK5, a kinase that phosphorylates cardiac β-adrenergic receptors and regulates G protein coupling and signaling. The GRK5 rs2230345 variant (Gln41Leu), which occurs at a much higher frequency in African ancestral populations, has been shown to increase the desensitization of the β1-adrenergic receptor, which in turn leads to lower receptor stimulation and cAMP production, essentially acting as endogenous β-blockade. Further studies assessing the combination of variants that influence risk for postoperative arrhythmia are warranted.

In conclusion, our data suggest that the ADRB1 Arg389Arg genotype may be useful in predicting risk for postoperative JET in pediatric patients undergoing cardiac surgery. Whether β-blockers may have a role in risk management of JET requires further study.
reduction in patients with the Arg389Arg genotype remains to be determined.

ACKNOWLEDGMENTS
The authors would like to thank the research participants for their participation. We would also like to thank Lisa Schnabel, Lynda Stauffer, and Cheryl Galloway for their logistical support throughout the project.

CONFLICT OF INTEREST
The authors declared no competing interests for this work.

AUTHOR CONTRIBUTIONS
L.D., J.D.D., and L.H.C. wrote the manuscript. L.D., M.C., T.L., D.H.Z., D.L., J.A.J., G.J.P., J.P.J., M.S.B., and L.H.C. designed the research. L.D., M.C., B.Q.D., D.H.Z., F.H., J.F.H., J.D., T.L., and C.M. performed the research. L.D. and F.H. analyzed the data.

REFERENCES
1. Lan Y-T, Lee JC, Wetzel G. Postoperative arrhythmia. Curr Opin Cardiol. 2003;18:73.
2. Moak JP, Arias P, Kaltman JR, et al. Postoperative junctional ectopic tachycardia: risk factors for occurrence in the modern surgical era. Pacing Clin Electrophysiol. 2013;36:1156-1168.
3. Dodge-Khatami A, Miller OL, Anderson RH, Gil-Jaurena JM, Goldman AP, de Leval MR. Impact of junctional ectopic tachycardia on postoperative morbidity following repair of congenital heart defects. Eur J Cardiothorac Surg. 2002;21:255-259.
4. Cools E, Missant C. Junctional ectopic tachycardia after congenital heart surgery. Acta Anaesth Belg. 2014;65:1-8.
5. Dodge-Khatami A, Miller OL, Anderson RH, et al. Surgical substrates of postoperative junctional ectopic tachycardia in congenital heart defects. J Thorac Cardiovasc Surg. 2002;123:624-630.
6. Andreasen J, Johnsen S, Ravn H. Junctional ectopic tachycardia after surgery for congenital heart disease in children. Intensive Care Med. 2008;34:895-902.
7. Madamanchi A. Beta-adrenergic receptor signaling in cardiac function and heart failure. McGill J Medicine Mjm Int Forum Adv Medical Sci Students. 2007;10:99-104.
8. Behar J, Ganesan A, Zhang J, Yaniv Y. The autonomic nervous system regulates the heart rate through cAMP-PKA dependent and independent coupled-clock pacemaker cell mechanisms. Front Physiol. 2016;7:419.
9. Mason DA, Moore DJ, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999;274:12670-12674.
10. Green SA, Turki J, Innis M, Liggett SB. Amino-Terminal polymorphisms of the human beta.2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry-US. 1994;33:9414-9419.
11. Dishy V, Sofowora GG, Xie HG, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med. 2001;345:1030-1035.
12. Jeff JM, Donahue BS, Brown-Gentry K, et al. Genetic variation in the beta1-adrenergic receptor is associated with the risk of atrial fibrillation after cardiac surgery. Am Heart J. 2014;167:101-108.
13. Ulucan C, Cetintas V, Tetik A, et al. beta1 and beta2-adrenergic receptor polymorphisms and idiopathic ventricular arrhythmias. J Cardiovasc Electrophysiol. 2008;19:1053-1058.
14. Pacanowski M, Gong Y, Cooper-DeHoff RM, et al. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther. 2008;84:715-721.
15. Johnson JA, Terra SG. Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics. Pharmaceut Res. 2002;19:1779-1787.
16. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genetics. 2003;73:1162-1169.
17. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genetics. 2001;68:978-989.
18. Al-Sofyani KA, Jamalaldeen RI, Abusaif SM, Ellassal A, Al-Radi OO. The prevalence and outcome of junctional ectopic tachycardia in pediatric cardiac surgery. J Egyptian Soc Cardio-Thoracic Surg. 2017;25:128-132.
19. Batra AS, Chun DS, Johnson TR, et al. A prospective analysis of the incidence and risk factors associated with junctional ectopic tachycardia following surgery for congenital heart disease. Pediatr Cardiol. 2006;27:51-55.
20. Mahmoud A-BS, Tantawy A, Kouatl IAA, Baslaim GM. Propranolol: a new indication for an old drug in preventing postoperative junctional ectopic tachycardia after surgical repair of tetralogy of Fallot. Interact Cardiovasc Thorac Surg. 2008;7:184-187.
21. Ismail MF, Arafat AA, Hamouda TE, et al. Junctional ectopic tachycardia following tetralogy of Fallot repair in children under 2 years. J Cardiothorac Surg. 2018;13:60.
22. Walsh EP, Saul JP, Sholler GF, et al. Evaluation of a staged treatment protocol for rapid automatic junctional tachycardia after operation for congenital heart disease. J Am Coll Cardiol. 1997;29:1046-1053.
23. Hoffmann TM, Bush DM, Wernovsky G, et al. Postoperative junctional ectopic tachycardia in children: incidence, risk factors, and treatment. Ann Thorac Surg. 2002;74:1607-1611.
24. 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68-74. doi:10.1038/nature15393
25. Esler M. The autonomic nervous system and cardiac arrhythmias. Clin Auton Res. 1992;2:133-135.
26. Janse M. Why is increased adrenergic activity arrhythmogenic? Berlin, Heidelberg: Springer; 1989;353-363.
27. Bar-Cohen Y, Silka MJ. Management of postoperative arrhythmias in pediatric patients. Curr Treat Options Cardiovas Med. 2012;14:443-454.
28. Thomas CD, Johnson JA. Pharmacogenetic factors affecting beta-blocker metabolism and response. Expert Opin Drug Metab Toxicol. 2020;16(10):953-964.
29. Fiuzat M, Neely ML, Starr AZ, et al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail. 2013;15:258-266.
30. Biolo A, Clausell N, Santos KG, et al. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol. 2008;102:726-732.
31. Iwai C, Akita H, Shiga N, et al. Suppressive effect of the Gly389 allele of the β1-adrenergic receptor gene on the occurrence of ventricular tachycardia in dilated cardiomyopathy. *Circ J*. 2002;66:723-728.

32. Kabbani MS, Taweel HA, Kabbani N, Ghamdi SA. Critical arrhythmia in postoperative cardiac children: Recognition and management. *Avicenna J Med*. 2017;7:88-95.

33. Kadam SV, Tailor KB, Kulkarni S, Mohanty SR, Joshi PV, Rao SG. Effect of dexmeditomidine on postoperative junctional ectopic tachycardia after complete surgical repair of tetralogy of Fallot: A prospective randomized controlled study. *Ann Cardiac Anaesth*. 2015;18:323-328.

34. El Amrousy DM, Elshmaa NS, El-Kashlan M, et al. Efficacy of prophylactic dexmedetomidine in preventing postoperative junctional ectopic tachycardia after pediatric cardiac surgery. *J Am Heart Assoc*. 2017;6:e004780.

35. Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. *Circulation Arrhythmia Electrophysiol*. 2013;6:137-143.

36. Borgman KY, Smith AH, Owen JP, Fish FA, Kannankeril PJ. A genetic contribution to risk for postoperative junctional ectopic tachycardia in children undergoing surgery for congenital heart disease. *Heart Rhythm*. 2011;8:1900-1904.

37. Kohout TA, Lefkowitz RJ. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. *Mol Pharmacol*. 2003;63:9-18.

38. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. *Nat Med*. 2008;14:510-517.

**How to cite this article:** Dumeny L, Chantra M, Langaee T, et al. β1-receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery. *Clin Transl Sci*. 2022;15:619–625. doi:10.1111/cts.13178